What Neuronomics does

Neuronomics AG is a privately held Swiss asset manager founded in 2015 and headquartered in Zug, Switzerland. The firm specializes in quantitative trading strategies that combine computational neuroscience research with artificial intelligence to detect in real-time market inefficiencies arising from evolutionary-biased human decision-making. Its core product, Neurofin, is a long-only cryptocurrency trading strategy launched in 2020 that the company reports has generated three times the risk-adjusted return of its market benchmark with a beta near zero over a four-plus year live track record.

The technology stack is built on proprietary neurofinance market models that translate academic research from computational neuroscience into quantitative trading algorithms, supported by co-founder expertise spanning a PhD in emotional decision-making from the University of Zurich and a PhD in computational neuroscience from EPFL. Strategies are packaged as Actively Managed Certificates (AMCs), allowing the firm to convert algorithmic models into tradable securities, and are distributed exclusively to professional investors with Swiss residence under Art. 10 Para. 3 CISA, with US persons explicitly excluded.

The business model is fee-based asset management on a single-product, single-jurisdiction platform, supplemented by custom-tailored strategy development for professional clients. With 1-10 employees, an operating geography limited to Switzerland, and personnel linkages to DeFi Technologies (Nasdaq: DEFT) via board and advisor overlap, Neuronomics operates as a specialized boutique combining academic neuroscience research, proprietary AI, and Swiss-regulated product structuring.

Name

Neuronomics

Legal name

Neuronomics AG

Website

https://neuronomics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Neuronomics AG is a Zug-based Swiss asset manager that uses AI and computational neuroscience to run quantitative trading strategies, principally the Neurofin long-only crypto strategy, distributed as Actively Managed Certificates to professional investors in Switzerland.

Ownership category

akta.pro rank

Headquarters

HQ city

Zug

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Asset Management Fees: Neuronomics operates as a Swiss asset manager generating revenue through management fees on quantitative trading strategies and structured investment products such as Actively Managed Certificates (AMCs). Revenue is earned from managing algorithmic trading portfolios for professional investors.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Neuronomics AG is a Swiss asset manager that develops and manages AI-driven quantitative trading strategies grounded in computational neuroscience. It transfers academic research on evolutionary-biased human brain processes into market models that detect short-term inefficiencies in real time, and packages its flagship Neurofin crypto long-only strategy as an Actively Managed Certificate (AMC) for professional investors in Switzerland.

Product overview

Neuronomics offers a single core investment product called Neurofin, a quantitative cryptocurrency trading strategy. Built on proprietary AI and computational neuroscience research, the strategy is designed as an Actively Managed Certificate (AMC) that transfers advanced trading algorithms into easily tradable investment products. The company develops personalized algorithmic trading strategies aligned with individual investor objectives, risk profiles, and market interests, with a focus on consistently outperforming market indices on a risk-adjusted basis.

Differentiator

Problem solved

Functional benefit

Brands

• Neurofin: A long-only crypto trading strategy designed to capitalize on short-term market inefficiencies caused by human biases in processing losses, gains, and uncertainties. Cryptocurrency markets provide the ideal environment for Neurofin to excel, as short-term price movements are heavily influenced by crowd psychology and neural decision-making patterns. Live for over four years, Neurofin has generated three times the risk-adjusted return of the market benchmark with a beta near zero.

Products and services

• Neurofin Neurofin is a long-only cryptocurrency trading strategy that capitalizes on short-term market inefficiencies caused by human biases in processing losses, gains, and uncertainties. Designed for professional investors in Switzerland and structured as an Actively Managed Certificate (AMC), it has been live since 2020 and, according to the company, has generated three times the risk-adjusted return of the market benchmark with a beta near zero. Cryptocurrency markets are targeted because short-term price movements are heavily influenced by crowd psychology and neural decision-making patterns.

Quantifiable outcome

• Three times risk-adjusted return vs market benchmark with near-zero beta
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• CoinShares: European crypto asset manager and ETP issuer that acquired XBT Provider (founded by Neuronomics board member Johan Wattenström); operates the same Swiss-rooted crypto investment product model and shares the institutional crypto-asset distribution focus.
• Pantera Capital: One of the longest-running crypto-focused hedge funds and venture firms; comparable as a specialist manager running systematic and discretionary crypto strategies, though US-domiciled and broader in mandate.
• 21Shares: Swiss-based issuer of crypto exchange-traded and actively managed products, structurally the closest analog to Neuronomics — both wrap proprietary crypto strategies into regulated Swiss-listed investment vehicles for professional and retail investors.
• Galaxy Digital: Public crypto-native asset manager and trading firm offering institutional crypto investment products and market-making; comparable as a specialist manager monetizing crypto market inefficiencies via systematic strategies.
• Crypto Finance (Deutsche Digital Assets): Swiss-regulated crypto asset manager and broker based in Zug offering institutional crypto investment products, structured products, and asset management — directly comparable in geography, regulatory framework, and target customer (Swiss professional investors).
• Valour (DeFi Technologies): Subsidiary of DeFi Technologies (Nasdaq: DEFT) issuing crypto ETPs, with shared board representation to Neuronomics via Johan Wattenström; directly comparable as a crypto structured-product issuer leveraging Swiss regulatory infrastructure.

Broad incumbents

• Man Group / AHL: Global quantitative asset manager (AHL) running systematic, model-driven trading strategies across multiple asset classes; comparable as a large incumbent in systematic/quant trading but with a much broader mandate and significantly larger AUM.
• Two Sigma: Large, established quantitative investment manager applying AI and data science to systematic trading across asset classes; comparable in its AI-driven quant trading approach but far broader in scale and asset coverage than Neuronomics' boutique crypto focus.

Regional players

• Sygnum: Swiss-regulated digital asset banking group offering institutional crypto asset management, trading, and tokenization services; comparable as a Switzerland-based digital-asset specialist serving professional investors, though broader in product scope than Neuronomics.
• Amina Bank: Swiss-regulated digital asset bank founded by Neuronomics board member Philipp Baretta; comparable as a Zug-based Swiss intermediary serving professional crypto investors, but operating as a bank rather than an asset manager.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/neuronomics-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuronomics